Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Contribution

Quantitative Assay for Human Cytoplasmic Islet Cell Antibodies

  1. George M Bright
  1. Department of Pediatrics, Medical University of South Carolina Charleston, South Carolina
  1. Address correspondence and reprint requests to George M. Bright, MD, Department of Pediatrics, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425.
Diabetes 1987 Oct; 36(10): 1183-1186. https://doi.org/10.2337/diab.36.10.1183
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

An assay for human islet cell antibodies (ICAs) in serum yielding numerical values and amenable to statistical evaluation has been developed utilizing fluorescence spectrophotomicroscopy (FSPM). The results of the blinded trials by FSPM were compared with those by standard indirect immunofluorescence (IFL). No false-positive or false-negative readings were obtained in 258 observations when the results by FSPM were compared with those by IFL. The intraand interassay variabilities encountered were not enough to misclassify a specimen. The presence of anti-thyroid, anti-adrenal, or anti-nuclear antibodies did not produce false-positive readings. Twenty-eight additional specimens from diabetic children were also analyzed via three blood group type O pancreases. There was complete agreement concerning the presence or absence of ICA between IFL and FSPM analyses. Analysis of the three pancreases yielded different numbers of results positive for ICA (14/28 vs. 22/28 vs. 15/28, P = .008) in both assays. Thus, selection of pancreatic substrate may influence the outcome of assays for ICA. A matrix of fluorescent microspheres has been devised that allows calibration of the FSPM system. Now, reproducible and comparable readings for ICA values can be obtained from the various reporting laboratories. Should an international reference serum for ICA become available, the remaining problem in the ICA assay, that of substrate (pancreas) variability, should be resolved.

  • Received September 3, 1986.
  • Revision received March 5, 1987.
  • Accepted March 5, 1987.
  • Copyright © 1987 by the American Diabetes Association

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this Issue

October 1987, 36(10)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Quantitative Assay for Human Cytoplasmic Islet Cell Antibodies
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Quantitative Assay for Human Cytoplasmic Islet Cell Antibodies
George M Bright
Diabetes Oct 1987, 36 (10) 1183-1186; DOI: 10.2337/diab.36.10.1183

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Quantitative Assay for Human Cytoplasmic Islet Cell Antibodies
George M Bright
Diabetes Oct 1987, 36 (10) 1183-1186; DOI: 10.2337/diab.36.10.1183
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Loss of Early Phase of Insulin Release in Humans Impairs Glucose Tolerance and Blunts Thermic Effect of Glucose
  • Adoptive Transfer of Insulitis and Diabetes in Neonates of Diabetes-Prone and -Resistant Rats: Tissue Localization of Injected Blasts
  • Effects of Glucose and Diabetes on Binding of Naloxone and Dihydromorphine to Opiate Receptors in Mouse Brain
Show more Original Contribution

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.